AN2 Therapeutics (ANTX) Preferred Dividend Payments (2021 - 2022)
AN2 Therapeutics (ANTX) posted quarterly Preferred Dividend Payments of $1.8 million for Q1 2022, up 139.16% year-over-year from $761000.0 in Q1 2021, and down 5.45% quarter-over-quarter from $1.9 million in Q4 2021.
Powered by 
Analysis
AN2 Therapeutics (ANTX) Preferred Dividend Payments (2021 - 2022) Analysis & Trends
AN2 Therapeutics (ANTX) has reported Preferred Dividend Payments for 2 consecutive years, with $1.8 million the latest figure, recorded in Q1 2022.
- In Q1 2022, Preferred Dividend Payments rose 139.16% year-over-year to $1.8 million; the TTM figure through Dec 2022 stood at $1.8 million (down 72.06% YoY), while the FY2022 annual figure was $1.8 million, down 72.06% from the prior year.
- Preferred Dividend Payments eased to $1.8 million in Q1 2022 per ANTX's latest filing, from $1.9 million in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $1.9 million in Q3 2021 and bottomed at $761000.0 in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | AN2 Therapeutics | 262.30 Mn | 262.30 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2022 | 1.82 Mn |
| Dec 31, 2021 | 1.93 Mn |
| Sep 30, 2021 | 1.93 Mn |
| Jun 30, 2021 | 1.90 Mn |
| Mar 31, 2021 | 761,000.00 |